JSM 2005 Online Program

Abstract #304734

This is the preliminary program for the 2005 Joint Statistical Meetings in Minneapolis, Minnesota. Currently included in this program is the "technical" program, schedule of invited, topic contributed, regular contributed and poster sessions; Continuing Education courses (August 7-10, 2005); and Committee and Business Meetings. This on-line program will be updated frequently to reflect the most current revisions.

To View the Program:
You may choose to view all activities of the program or just parts of it at any one time. All activities are arranged by date and time.

The views expressed here are those of the individual authors
and not necessarily those of the ASA or its board, officers, or staff.

The Program has labeled the meeting rooms with "letters" preceding the name of the room, designating in which facility the room is located:

Minneapolis Convention Center = “MCC” Hilton Minneapolis Hotel = “H” Hyatt Regency Minneapolis = “HY”

Back to main JSM 2005 Program page

Legend:

= Applied Session,

= Theme Session,

= Presenter

Activity Number:	494
Type:	Contributed
Date/Time:	Thursday, August 11, 2005 : 8:30 AM to 10:20 AM
Sponsor:	Section on Statistics in Epidemiology
Abstract - #304734
Title:	Profiles of Cox-2 Users and Nonusers
Author(s):	Brian L. James*+
Companies:	Pfizer, Inc./UMDNJ
Address:	1235 Jeanette Ave, Union, NJ, 07083, United States
Keywords:	Cox-2 ; Vioxx ; Celebrex ; NSAID ; heart disease ; NHANES
Abstract:	In 1999, a category of drugs known as Cox-2 inhibitors was approved by the FDA for relieving acute pain arising from osteoarthritis, rheumatoid arthritis, and other inflammatory conditions while causing fewer gastrointestinal side effects. But starting in late 2004, these drugs faced an onslaught of negative publicity over evidence of increased risk of heart attack and stroke detected in certain clinical trials. As a result, Vioxx (rofecoxib) was withdrawn from the market, the market-leader Celebrex (celecoxib) stopped advertising, and Bextra (valdecoxib) was banned by one of the largest HMOs. Even over-the-counter pain reliever Aleve (naproxen) that is not Cox-2 specific but belongs to the broader class of nonsteroidal antiinflammatory drugs (NSAIDs), has come under fire. In this paper, we examine the demographic and medical profiles of Cox-2 users and nonusers based on data from a large cross-sectional epidemiologic study, the National Health and Nutrition Examination Survey. We attempt to identify those medical conditions and other covariates associated with Cox-2 usage.

The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.

Back to the full JSM 2005 program